Evaluating treatment efcacy in a mouse model of enterovirus d68-associated paralytic myelitis

Journal of Infectious Diseases

Volumn 216, Issue 10, 2017, Pages 1245-1253

  Hixon, Alison M ^a,b   Clarke, Penny ^c   Tyler, Kenneth L ^c,d  

^a Medical Scientist Training Program   (United States)

^b Neuroscience Program   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Department of Medicine ^*  (United States)

Author keywords

Acute flaccid myelitis; Enterovirus D68; Mouse model; Paralysis; Therapies

Indexed keywords

DEXAMETHASONE; FLUOXETINE; GAMUNEX C; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; SEROTONIN UPTAKE INHIBITOR; VIRUS ANTIBODY;

ACUTE FLACCID MYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ATAXIA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; ENTEROVIRUS D68; MORTALITY; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MOUSE; MOUSE MODEL; MYELITIS; NEWBORN; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LOAD; ANIMAL; BLOOD; DISEASE MODEL; ENTEROVIRUS D; IMMUNOLOGY; PATHOPHYSIOLOGY; SERODIAGNOSIS; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DEXAMETHASONE; DISEASE MODELS, ANIMAL; ENTEROVIRUS D, HUMAN; FLUOXETINE; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MYELITIS; NEUTRALIZATION TESTS; PARALYSIS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85039862472     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix468     Document Type: Conference Paper

References (46)

1. Oberste MS, Maher K, Schnurr D, et al. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol 2004; 85:2577-84.
2. Blomqvist S, Savolainen C, Råman L, Roivainen M, Hovi T. Human rhinovirus 87 and enterovirus 68 represent a unique serotype with rhinovirus and enterovirus features. J Clin Microbiol 2002; 40:4218-23.
3. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA; Centers for Disease Control and Prevention. Enterovirus surveillance-United States, 1970-2005. MMWR Surveill Summ 2006; 55:1-20.
4. Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol 1967; 85:297-310.
5. Tokarz R, Firth C, Madhi SA, et al. Worldwide emergence of multiple clades of enterovirus 68. J Gen Virol 2012; 93:1952-8.
6. Holm-Hansen CC, Midgley SE, Fischer TK. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis 2016; 16:e64-75.
7. Messacar K, Abzug MJ, Dominguez SR. The emergence of enterovirus-D68. Microbiol Spectr 2016; 4:105-19.
8. Aliabadi N, Messacar K, Pastula DM, et al. Enterovirus D68 infection in children with acute faccid myelitis, Colorado, USA, 2014. Emerg Infect Dis 2016; 22:1387-94.
9. Greninger AL, Naccache SN, Messacar K, et al. A novel outbreak enterovirus D68 strain associated with acute faccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis 2015; 15:671-82.
10. Leshem E. Notes from the feld: acute faccid myelitis among persons aged
11. Messacar K, Abzug MJ, Dominguez SR. 2014 outbreak of enterovirus D68 in North America. J Med Virol 2016; 88:739-45.
12. Messacar K, Schreiner TL, Van Haren K, et al. Acute fac-cid myelitis: a clinical review of US cases 2012-2015. Ann Neurol 2016; 80:326-38.
13. Midgley CM, Watson JT, Nix WA, et al. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation. Lancet Respir Med 2015; 3:879-87.
14. Millichap JG. Acute faccid myelitis outbreak. Pediatr Neurol Briefs 2015; 29:96.
15. Pastula DM, Aliabadi N, Haynes AK, et al.; Centers for Disease Control and Prevention (CDC). Acute neuro-logic illness of unknown etiology in children-Colorado, August-September 2014. MMWR Morb Mortal Wkly Rep 2014; 63:901-2.
16. Sejvar JJ, Lopez AS, Cortese MM, et al. Acute faccid myelitis in the United States, August-December 2014: results of nationwide surveillance. Clin Infect Dis 2016; 63:737-45.
17. Van Haren K, Ayscue P, Waubant E, et al. Acute faccid myelitis of unknown etiology in California, 2012-2015. JAMA 2015; 314:2663-71.
18. Centers for Disease Control and Prevention. Acute faccid myelitis: AFM in the United States. http://www.cdc.gov/acute-faccid-myelitis/afm-surveillance.html. Accessed 2 August 2017.
19. Maloney JA, Mirsky DM, Messacar K, Dominguez SR, Schreiner T, Stence N V. MRI fndings in children with acute faccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am J Neuroradiol 2015; 36:245-50.
20. Hovden IA, Pfeifer HC. Electrodiagnostic fndings in acute faccid myelitis related to enterovirus D68. Muscle Nerve 2015; 52:909-10.
21. Messacar K, Robinson CC, Pretty K, Yuan J, Dominguez SR. Surveillance for enterovirus D68 in colorado children reveals continued circulation. J Clin Virol 2017; 92:39-41.
22. Wang G, Zhuge J, Huang W, et al. Enterovirus D68 subclade B3 strain circulating and causing an outbreak in the United States in 2016. Sci Rep 2017; 7:1242.
23. Yoder JA, Lloyd M, Zabrocki L, Auten J. Pediatric acute fac-cid paralysis: enterovirus D68-associated anterior myelitis. J Emerg Med 2017; 53:e19-e23.
24. Antona D, Kossorotof M, Schufenecker I, et al. Severe pae-diatric conditions linked with EV-A71 and EV-D68, France, May to October 2016. Euro Surveill 2016; 21:30402.
25. Cabrerizo M, García-Iñiguez J P, Munell F, et al. First cases of severe faccid paralysis associated with enterovirus D68 infection in Spain, 2015-2016. Pediatr Infect Dis J 2017. In press.
26. Carrion Martin AI, Pebody RG, Danis K, et al. The emergence of enterovirus D68 in England in autumn 2014 and the necessity for reinforcing enterovirus respiratory screening. Epidemiol Infect 2017; 145:1855-64.
27. Crone M, Tellier R, Wei XC, et al. Polio-like illness associated with outbreak of upper respiratory tract infection in children. J Child Neurol 2016; 31:409-14.
28. Dyrdak R, Grabbe M, Hammas B, et al. Outbreak of entero-virus D68 of the new B3 lineage in Stockholm, Sweden, August to September 2016. Euro Surveill 2016; 21:pii: 30403.
29. Knoester M, Scholvinck EH, Poelman R, et al. Upsurge of enterovirus D68, the Netherlands, 2016. Emerg Infect Dis 2017; 23:140-3.
30. Stacpoole SRL, Molyneux A, Bäumer D. Acute segmen-tal poliomyelitis-like faccid paralysis in an adult in the UK, associated with enterovirus D68. Pract Neurol 2017; 17:297-301.
31. Yip CCY, Lo JYC, Sridhar S, et al. First report of a fatal case associated with EV-D68 infection in Hong Kong and emergence of an interclade recombinant in China revealed by genome analysis. Int J Mol Sci 2017; 18:E1065.
32. Pérez G, Rosanova MT, Freire MC, et al. Unusual increase of cases of myelitis in a pediatric hospital in Argentina. Arch Argent Pediatr 2017; 115:364-9.
33. Martin JA, Messacar K, Yang ML, et al. Outcomes of Colorado children with acute faccid myelitis at 1 year. Neurology 2017; 89:129-37.
34. Hixon AM, Yu G, Leser JS, et al. A mouse model of paralytic myelitis caused by enterovirus D68. PLoS Pathog 2017; 13:e1006199.
35. Rhoden E, Zhang M, Nix WA, Oberste MS. In vitro ef-cacy of antiviral compounds against enterovirus D68. Antimicrob Agents Chemother 2015; 59:7779-81.
36. Ulferts R, van der Linden L, Tibaut HJ, et al. Selective serotonin reuptake inhibitor fuoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother 2013; 57:1952-6.
37. Macaya A, Felipe-Rucián A. Enterovirus and neurological complications. An Pediatr (Barc) 2017; 86:107-9.
38. Hurley D. After a lull last year, reports of acute faccid myelitis surge in 2016. Neurology Today 2016; 16:1, 21-3.
39. Goody RJ, Schittone SA, Tyler KL. Experimental reovi-rus-induced acute faccid paralysis and spinal motor neuron cell death. J Neuropathol Exp Neurol 2008; 67:231-9.
40. Zhang Y, Moore DD, Nix WA, Oberste MS, Weldon WC. Neutralization of enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products. J Clin Virol 2015; 69:172-5.
41. Gromeier M, Wimmer E. Mechanism of injury-provoked poliomyelitis. J Virol 1998; 72:5056-60.
42. Tyler KL. Rationale for the evaluation of fuoxetine in the treatment of enterovirus D68-associated acute faccid myelitis. JAMA Neurol 2015; 72:493-4.
43. Strauss WL, Unis AS, Cowan C, Dawson G, Dager SR. Fluorine magnetic resonance spectroscopy measurement of brain fuvoxamine and fuoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiatry 2002; 159:755-60.
44. Wilens TE, Cohen L, Biederman J, et al. Fluoxetine phar-macokinetics in pediatric patients. J Clin Psychopharmacol 2002; 22:568-75.
45. Fitch MT, van de Beek D. Drug Insight: steroids in CNS infectious diseases-new indications for an old therapy. Nat Clin Pract Neurol 2008; 4:97-104.
46. Sun L, Meijer A, Froeyen M, et al. Antiviral activity of broad-spectrum and enterovirus-specifc inhibitors against clinical isolates of enterovirus D68. Antimicrob Agents Chemother 2015; 59:7782-5.